Abstract:Background: Arsenic trioxide (ATO) is widely used for acute promyelocytic leukemia (APL) treatment, but it can’t show satisfactory efficacy in non-APL leukemia. Aquaporin-9 (AQP9), a transmembrane transporter, is required for ATO uptake. Acute myeloid leukemia (AML) other than APL cells express relatively lower levels of AQP9, which limits the cytotoxic activity of ATO in those types of leukemia cells. Recently, we found that granulocyte colony stimulating factor (G-CSF) can upregulate the expression of AQP9. … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.